A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

To join this study, your child needs to have been diagnosed with eczema for a certain amount of time before the study starts. For children aged 6 years and older, they need to have had eczema for at least 12 months. For those aged 2 to under 6 years, it's at least 6 months, and for babies and toddlers aged 6 months to under 2 years, it's at least 3 months. Their eczema also needs to be considered 'moderate to severe' by the study doctors based on specific assessments of their skin.

There are also some reasons why someone might not be able to join. For example, if your child has recently taken part in another medical study involving a new medicine in the last 8 weeks, they usually can't join this one. Also, treatments like certain eczema medications (like dupilumab) or specific vaccinations received shortly before the study might mean your child can't take part, at least for a period of time. The study team will review all of these details carefully with you.

If your child participates, they will be given either the new medicine (lebrikizumab), a dummy medicine (placebo), or a standard eczema cream called a topical corticosteroid. You won't know which one your child is receiving, and this is standard practice in clinical trials to ensure fair results. Your child will have regular visits to the clinic where doctors and nurses will monitor their eczema, take measurements (like blood tests), and check how they are feeling. These visits help us track how the treatment is working and if there are any side effects. The total duration of your child's involvement in the study will be explained in full by the study team, including how long the treatment period lasts and any follow-up appointments.